RFLNYSEPharmaceutical PreparationsFiscal year ends July 31
Rafael Holdings, Inc.
Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 11, 2026
$1.29−0.10 (-7.19%)
Close on Oct 19, 2026
- Market cap
- $66.09M
- P/E (TTM)
- –
- Dividend yield
- –
Rafael Holdings, Inc. revenue by segment
By business segment
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Real Estate [Member] | -$50.00K | $80.00K | – | – | – | – | – | – | – | -162.5% |
| Infusion Technology [Member] | -$3.82M | -$675.00K | – | – | – | – | – | – | – | +465.2% |
| Healthcare [Member] | -$25.29M | -$102.03M | – | – | – | – | – | – | – | -75.2% |
| Pharmaceuticals [Member] | – | – | – | – | – | – | -$1.61M | -$1.06M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Rafael's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.